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ABSTRACT
Whole-body 123I-Metaiodobenzylguanidine (mIBG) scintigraphy is used as the primary image modality in
neuroblastoma detection. It is the most sensitive and specific method for staging and response evaluation.
Validated semi-quantitative scoring methods with low interobserver variability and high reproducibility have
shown to be indispensable for the evaluation of response to therapy. However, low resolution, noise and
acquisition difficulties, specially in children, make low definition scans. These facts increase observer
dependent interpretations that limit assessment and complicate to put a scoring method succesfully into
practice. It is essential to have an objective and reliable measure of response to test the activity of therapies.
In this paper we propose the use of a quantitative observer-independent measurement of the strength of
uptake to be used as an additional tool for assisting the International Society of Paediatric Oncology Europe
Neuroblastoma Group (SIOPEN) semi-quantitative scoring method. This is the scoring method recommended
by the SIOPEN Nuclear Medicine and Physics Committee, in collaborative work with the Children’s Oncology
Group, as the standard one for acquiring and reporting diagnostic paediatric mIBG scans across Europe. Our
proposed method is based on the ratio between the amount of specific uptake at tumours and the amount of
non-specific uptake at SIOPEN anatomical sectors which has shown to be constant in all the scans of the
patients.
Keywords: image analysis, mIBG, neuroblastoma, quantitative assessment, scintigraphy.
INTRODUCTION
Neuroblastoma stands out among paediatric solid
tumours because of its relative frequency. It is the third
most common malignant solid tumour of childhood
(Mueller et al., 2013) and it is metastatic in half of
the patients at diagnosis, making accurate evaluation
of metastatic sites challenging (Matthay et al., 2010).
Anatomic imaging methods, such as computerized
tomography (CT) and magnetic resonance imaging
(MRI), are most useful for evaluation of the primary
tumour mass and nearby involved lymph nodes.
Functional imaging radioactive tracers, such as 123I-
mIBG, 18F-FDG, and 99mTc-MDP, are used to assess
the extent of disease and to search for distant
metastases (Sharp et al., 2013).
123I-mIBG scintigraphy remains the most specific
and sensible imaging modality of staging and
response evaluation (virtually 100% of specificity)
(Charron, 2013). It is essential in the management
of neuroblastoma. mIBG enters neuroendocrine cells
by an active uptake mechanism via the epinephrine
transporter and is stored in the neurosecretory
granules, resulting in a specific concentration in
contrast to cells of other tissues.
The pathological distribution of 123I-mIBG is
described as uptake in the primary tumour and in the
metastatic sites (Bombardieri et al., 2010). High peaks
of intensity are to be observed at location of 123I-
mIBG avid tissues. This is called specific uptake. Non-
specific uptake is also observed at the whole body as
a light homogeneous uptake pattern without peaks. It
is due to the 123I-mIBG travelling in the bloodstream
until it is excreted.
In order to evaluate the prognostic effects
and quantify efficacy of therapy, numerous semi-
quantitative scores have emerged (Ady et al., 1995;
Frappaz et al., 2000; Messina et al., 2006; Lewington
et al., 2009; Yanik et al., 2013; Decarolis et al.,
2013) although none of them has shown to be superior
to the others for quantification of response to the
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treatment (Matthay et al., 2010). In 2004, nuclear
medicine physicians and oncologists of the major
cooperative groups from North America, Australia,
New Zealand, Europe, China and Japan formed the
International Neuroblastoma Risk Group (INRG).
One of INRG’s goals was to reach international
consensus for standardized procedures for performing
and scoring 123I-mIBG scans to minimize subjective
assessments and improve the concordance between
readers. The use of a semi-quantitative score has
shown to be essential for evaluation of the efficacy of
therapy (Brisse et al., 2011).
All these methods divide the skeleton into
anatomical sectors, then give each sector an individual
score for number of metastatic sites and strength of
uptake. They have achieved good correlation with
outcome. Intensity at uptake sites is usually scored as
doubtful, definite, obvious or strong based upon the
observer assessment in comparison to liver or other
soft tissues.
But 123I-mIBG images have low definition,
specially in paediatric neuroblastoma. Consecutive
scans from the same patient may display variations of
intensity. This is caused by a number of factors such as
changes in the accumulation of radioisotopes during
each examination, changes in the gamma camera, the
volume of water intake, patient motion, the amount
of urine excreted or the response to treatment. In
addition, noise is also an important factor degrading
scintigraphic images (Hannequin and Mas, 2002;
Krom et al., 2013).
These factors limit the succesful application of
the scoring methods, although they are diminished
by strictly following the standarized guidelines for
preparing the patient for the acquisition process
defined in (Bombardieri et al., 2010). In Spain, La Fe
Hospital is the center of reference for neuroblastoma
and it is trying to institute the semi-quantitative scoring
method recommended for the International Society
of Paediatric Oncology Europe Neuroblastoma Group
(SIOPEN; Lewington et al., 2009; 2011; Ladenstein
et al., 2011) for neuroblastoma management. This
method is being developing by the Nuclear Medicine
and Physics Committee, in collaborative work with
the Children’s Oncology Group, for acquiring, reading
and scoring paediatric mIBG scans. This collaborative
group is setting the standards for the paediatric MIBG
scans across Europe. The problems arise when image
definition is poor. The disappearance or decreased
intensity of a lesion could be very subjective in
such cases and then intensity measurements show low
concordance between different observers.
It is possible that response to therapy exists
although it is too light to be visible for the human eye.
On the other hand, it is possible to have a light increase
in uptake at a new metastatic site but not high enough
to be clearly identified.
An objective measurement between specific
uptake at the regions of interest (ROIs) such as
tumours, metastases, etc. and non-specific uptake at a
region of reference is needed. It could lead to a better
identification and stratification of the cases.
First observer independent attempts to quantify
uptake in ROIs in scintigraphies were made in (Maisey
et al., 1973) where an uptake measurement of 99mTc in
thyroid studies based on the number of gamma photons
detected (counts) was proposed. The main idea was to
calculate the ratio between counts in ROI and the total
body counts.
This idea is used in heart-to-mediastinal (H/M)
uptake ratio derived from mIBG scintigraphy by
providing a quantitative measurement of uptake with
success to monitor response to medical treatment in
cardiac sympathetic imaging (Inoue et al., 2013).
The H/M ratio is in widespread use, however,
there are variations among publications from various
institutions because of several factors (Chen et al.,
2011; Bulten et al., 2012), especially, the way the ROIs
are placed.
Computer-aided applications for automatic
assessment of 99mTc bone scintigraphic images have
been developed as well. In them, brightness is used
with success for feature identification. For instance, in
Yin and Chiu (2004), local maximum of brightness
in bones and its asymmetries are used to detect
abnormalities in skeleton in 99mTc whole body bone
scintigraphies.
Later in Jia-Yann et al. (2007), a set of algorithms
was also proposed for segmentation and lesion
grey level determination in 99mTc whole body bone
scintigraphies. In this work, after smoothing noise and
segmenting skeleton, the lesion grey level is used as an
evidence of the existence of uptake. They used a set of
previous measurements of pixel’s intensity mean and
standard deviation at different body parts in a set of
100 patients to create a grey level of reference. Then,
any ROI could be measured in another patient and
compared with the estimated normal grey level. The
larger the standard deviation value of grey level is at a
given region, the greater the possibility of bone lesion
existence is.
99mTc and 123I-mIBG are similar scintigraphic
procedures and in both brightness is the primary tool
used for abnormal region identification. Nevertheless,
images obtained in 99mTc scans are very different from
123I-mIBG due to a combination of diverse factors,
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the most important of which being that different
radiopharmaceuticals have different biodistributions.
For instance, previous work on bone segmentation
with 99mTc bone scintigrams in Sajn et al. (2005) based
on detecting edges is not applicable as a general rule
in paediatric neuroblastoma 123I-mIBG scintigraphies
because bones are not always visible. Skeletal uptake
is only visible in neuroblastoma in those patients with
bone metastases. Thus, a quantitative measurement
method that works even when no bones are visible in
scan is required.
This brings out that application of techniques to
improve image quality such as image enhancement
based on histogram with successful application in
detection of lesions in 99mTc scintigraphies Jeong
et al. (2011) seems not being useful in 123I-mIBG of
children in neuroblastoma detection. In Wesolowski
et al. (2005), although the Poisson noise level
was reduced, nuclear medicine physicians preferred
original (not processed) planar images rather than the
processed version due the blur effect on features and
general image degradation.
As a result of the above, the algorithms
successfully used in 99mTc are not directly applicable
in 123I-mIBG. Nevertheless, the use of pixel’s intensity
mean and standard deviation at different body parts
is also useful in 123I-mIBG. In Martı´nez-Dı´az et al.
(2013), an observer independent method for measuring
the uptake level in any body region was introduced.
The technique enables the measurement of the relative
amount of uptake with a quantitative unit based on the
ratio between uptake at neuroblastoma tumours and
metastases and the rest of the tissues.
In this paper, we analyse the use of this
observer independent computerized procedure for the
measurement of the strength of uptake as an additional
tool to assist the SIOPEN semi-quantitative scoring
method. Our approach is based on the ratio between
the specific uptake at tumours or metastases and the
non-specific constant uptake threshold of the rest of
tissues at the SIOPEN body sector where a tumour
is located. Regional comparison of uptake at tumour
to uptake at predefined areas, such as the SIOPEN
anatomical sectors, instead of the comparison to the
local lesion site facilitates the repetitiveness of the
process as it sets a fixed point of reference that helps
in eliminating observer dependent variabilities.
This paper is structured as follows. In section
Materials and Methods, we detail the proposed
application of the measurement method defined in
Martı´nez-Dı´az et al. (2013) in the anatomical division
defined by the SIOPEN semi-quantitative scoring
method (Lewington et al., 2009; 2011; Ladenstein
et al., 2011). Experimental results are provided in
section Results, followed by discussion of the results
in section Discussion and conclusions being drawn in
section Conclusions.
MATERIALS AND METHODS
The experimental set contains twenty-seven 123I-
mIBG scintigraphies of 10 patients under 14 years old,
labeled PA1 to PA10, suffering from neuroblastoma.
Images were acquired at La Fe Hospital by its
Nuclear Medicine Unit following the standardized
guidelines described in (Bombardieri et al., 2010)
after a slow intravenous injection of 123I-mIBG (Dose:
100 µCi/Kg) and using different scintillation cameras
set to a photopeak equal to the principal gamma photon
emitted, that is, of 159 keV. A minimum of 250000 and
a maximum of 500000 photon counts were obtained
for each anterior and posterior views. The use of these
scintigraphies for this study was approved by the La Fe
Hospital’s Biomedical Research Ethics Committee.
Fig. 1. SIOPEN semi-quantitative scoring method
divides the skeleton into 12 anatomic segments as
shown. On the central images, anterior views of patient
PA2 taken at pre chemotherapy time T1, and at time T2
after it, with the sectors of the anatomic division made
for our anaylisis. On the right, image with only the
body frame IBF created from the 12 sectors extracted
from scan T2.
The scan produces two planar images, the anterior
and the posterior views. For every patient we have a
scintigraphy in time T1 pre chemotherapy and another
one post it in time T2. For some patients we have
more scans, for example for patient PA4, we have
four successive scans T1 to T4. The group of 123I-
mIBG scans from each patient were interpreted by
the nuclear medicine physicians of La Fe Hospital
following current guidelines in (Bombardieri et al.,
2010).
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This assessment is made in terms of description
of the position of the lesions when they are visible
on a given scan and, in consecutive scans of same
patient, for each lesion previously detected, they
include whether, in their appraisal, the lesion is more or
less intense than in previous scans or if it is not visible
any longer.
In planar image, the objective evidence of a
tumour or metastasis is a peak of counts compared
with local area counts average. For instance, tumours
labeled as ROI1,ROI2,ROI3 and ROI4 in the series of
scintigraphies shown in Fig. 2 are visible because of
the high number of photons detected at their exact
positions, greater than the average in the surroundings
of tumours. Instead of using the surroundings of each
tumour, that could be observer-dependent, we will
test the use of each anatomical sector defined by the
SIOPEN method as the predefined area for computing
that local area counts average of reference for every
ROI inside it.
In both views of every test scintigraphy, patient’s
body SIOPEN sectors (Lewington et al., 2009; 2011;
Ladenstein et al., 2011) are identified in an image by
placing a rectangle to delimit them: skull, thoracic
cage, proximal right upper limb, distal right upper
limb, proximal left upper limb, distal left upper limb,
spine, pelvis, proximal right lower limb, distal right
lower limb, proximal left lower limb and distal left
lower limb as shown in Fig. 1. Then we split the
original scintigraphy into 12 images identified as
I1, I2, ..., I12, one for each subimage of each sector in
the original scan. We do that on both views.
We identify the image of the whole trunk as IT
which is the union of SIOPEN Sectors 2 and 8 (see
Figs. 1 and 2). We will use IT in order to facilitate
taking measurements of uptake at the liver, where
uptake is usually present, and to compare it with
measurements of uptake at tumours or other ROIs in
trunk. We also define IBF as the image of the body
frame formed by extracting the subimages of all the
SIOPEN sectors from original scintigraphy. IBF is a
new image of the same size as the original scan which
only contains patient’s body sectors and the rest of the
image is blank.
The liver and each tumour and metastatic region
identified by phisicians of each patient are asigned to
the SIOPEN sector where they are located. For each
of them, we label regions as {Liver,ROI1,..., ROINi},
where Ni is the number of ROIs at each specific patient
i, 1≤ i≤ 10.
Fig. 2. IT sectors of scans of patient PA4 in time T1 to
T4 with ROIs selected inside circles labeled from 1 to 4.
On top, anterior IT views and on bottom the posterior
ones.
Let xi j be the intensity (number of photon counts)
at coordinates (i, j) in any body sector Ik with k ∈
{1,2, ...,12,T,BF} that represents radionuclide uptake
by tissue at these coordinates. We denote by I¯k and σIk
the average and standard deviation of Ik respectively.
In order to compare the count value xi j at pixel
(i, j) ∈ Ik with count value x′i j at same patient’s body
coordinates in successive scintigraphies, we need both
values transformed into the same uptake scale.
We will transform the number of photons counted
at each pixel xi j into its Z-Score value ZIk(i, j) in
reference to its SIOPEN sector counts average I¯k which
will allow us to take objective and comparable uptake
measurements,
ZIk(i, j) =
xi j− I¯k
σIk
. (1)
The brighter the pixels in the tumour are, the
further they are above the average of sector I¯k. So
our interest must focus in singling out those xi j
values that are greater than I¯k because they are very
relevant uptake points. Consequently, we will use the
transformation of Eq. 1 as in (Martı´nez-Dı´az et al.,
2013) but now applied to each SIOPEN sector:
QIk(i, j) = max(ZIk(i, j),0) . (2)
For the uptake measurement method to work
properly, it is important to take into account only those
pixels of image which unambiguously belong to the
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body frame, discarding pixels off the frame which have
a value xi j whose origin is unknown (noise outside
body frame).
For each image Ik, we denote by Z¯Ik the average
of {ZIk(i, j) : (i, j) ∈ Ik} and by Q¯Ik the average of{QIk(i, j) : (i, j) ∈ Ik}. ZIk transforms Ik values into
a new scale with zero mean and one as standard
deviation. When applied to a data of a normal
distribution, Z¯Ik is defined by
1√
2pi
∫ ∞
−∞
xe−x
2/2 dx = 0 ,
and Q¯Ik , the average of the normalized values of those
original values which were above the original average
is a constant that could be calculated as
1√
2pi
∫ ∞
−∞
u(x)xe−x
2/2 dx =
1√
2pi
∫ ∞
0
xe−x
2/2 dx
= 0.39894 ,
where u(x) is the Heaviside step function.
This means that, on average, the values that are
above the mean have a normalized value of 0.39894
which we round to 0.40. This value is a threshold
of reference for the intensity. Any point with a value
greater than of 0.40 has a value abnormally high in its
sector.
With these prerequisites we are able to take
objective measurements at the image of any region
inside a SIOPEN sector and compare them with the
next scintigraphies of the same patient. We will test
the use of Q¯Ik as the threshold of reference of specific
uptake (tumour or metastases) at each SIOPEN sector
and at IT . We will test as well the use of Z¯IBF as a
reference for comparing any region between different
scintigraphies.
We are interested in taking measurements of the
regions with specific uptake previously identified by
physicians and of other predefined areas such as the
liver. These measurements of the liver are used in semi-
quantitative scoring methods as a reference for the
specific uptake.
In Martı´nez-Dı´az et al. (2013), the next expression
was introduced for measuring any ROI# of the image.
We adapt it for taking measurements in reference to the
SIOPEN sector where the ROI is located:
Q¯Ik(ROI#) =
∑{QIk(i, j) : (i, j) ∈ ROI#}
Cd(ROI#)
, (3)
where Cd(ROI#) denotes the number of elements of
ROI# and k ∈ {1, ...,12,T,BF}.
Q¯Ik(ROI#) always takes positive values and it
quantifies how higher ROI# is above the average of
counts I¯k of the SIOPEN sector k where it is located.
In order to assist staff in taking an objective
and repeatable measurement of a given ROI#, at the
moment of putting Eq. 3 into practice, it is important
to unambiguously identify the exact points belonging
to that ROI#.
As main evidence of tumour is the peak of counts,
points unambiguosly belonging to it are bound to be
closer to the maximum intensity at the body area where
it is located.
Fig. 3. Example of the process of taking quantitative
measurements of any ROI in patients PA1,PA2,PA6
and PA7. Each ROI is demarcated inside a rectangle
(WROI#) close-fitted to it. Results are shown in Table 3.
Formally, assuming a given ROI# is located within
a SIOPEN sector Ik, we denote by WROI# a rectangle
around the whole ROI#, and only that ROI#, where
it is included (see Fig. 3). This rectangle should be
placed close-fitted to the shape of the ROI#. If point
at coordinates (i, j) ∈WROI# belongs to that ROI, then
intensity xi j ∈ [XROIthres,XROImax] where XROImax is the
maximum value for intensity in WROI# and XROIthres
with XROIthres < XROImax is the value of the minimum
intensity for the ROI#. Consequently, we consider the
following ROI# membership set:
ROI# = {∀(i, j) ∈WROI# : xi j ∈ [XROIthres,XROImax]} .
(4)
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The value of XROIthres is unknown. As an
approximation, we could consider it in reference
to XROImax. This will lead us to a more observer
independent measurement. For instance, we could fix
XROIthres = 0.75XROImax. For simplicity, we will follow
the criterion of selecting it equal to the minimum
intensity in WROI# . In practice, this will lead to different
measurements of the same ROI# depending on the
placement of WROI# so that it should be close-fitted to
the shape of it.
Besides measuring Q¯Ik(ROI#), in our tests we also
take measurements of the normalized ZIk(i, j) values of
the points belonging to the ROI#. We define Z¯Ik(ROI#)
as
Z¯Ik(ROI#) =
∑{ZIk(i, j) : (i, j) ∈ ROI#}
Cd(ROI#)
, (5)
where Cd(ROI#) denotes the number of elements of
the ROI# and k ∈ {1, ...,12,T,BF}.
Z¯Ik(ROI#) takes positive and negative values.
Negative measurements indicate that points in the
selected ROI# have lower values in average than I¯k.
Positive measurements indicate the contrary.
In order to take objective measurements of any
region of the body and to compare it to any other region
located in any body part of the same or other scan, we
should use the measurement related to the body frame
IBF , that is, Z¯IBF (ROI#).
Hence for every ROI# we can take quantitative
measurements with respect to the SIOPEN sector
where it is located as well as to the whole body frame
IBF .
In case a tumour is visible in both views, it has
two measurements, one referenced to I¯k of the anterior
view and the one referenced to the posterior view, as
shown in Fig. 2.
RESULTS
Table 1 collects Sectors Q¯Ik and Z¯Ik example
measurements in test patient PA2 shown in Fig. 1. At
both scans, T1 pre-therapy and T2 post it, reference
values are similar at both views and close to the
expected values 0.40 and 0.00. Similar results were
observed in the whole test set as shown in Fig. 4 where
the trunk sectors IT of patients PA2,PA4 and PA5 are
shown as an example. Although the radiodistribution
is very different in each patient, the values Z¯IT and Q¯IT
are similar in every one as expected.
Table 2 shows a comparison between quantitative
measurements and qualitative inform in patient PA4
(Fig. 2). Z¯IT and Z¯IBF values are 0.00 in all the four
PA4 scans T1 to T4 although they presented variations
in the intensity average I¯T . Each Q¯IT (ROI#) along the
series of PA4 is an objective evidence of tumour uptake
evolution. Q¯IT (ROI#) and Z¯IT (ROI#) measurements
correlate well with qualitative ranks (visible or not,
more or less intense, etc.) giving precise information
of uptake change, that is, a positive increment when
the peak is more intense and negative on the contrary.
What is more, quantitative measurements Q¯IT (ROI#)
give more intuitive information about the amount
of uptake in tumours in reference to local sector
counts average I¯T . Values of Q¯IT (ROI#) close to 0.00
imply light almost not visible uptake. Values from
0.00 to 0.40 mean higher but still light uptake in
comparison to the count average I¯T . Finally, values of
Q¯IT (ROI#) greater than 0.40 belong to a high uptake
ROI#, abnormally higher than expected in sector, in
comparison to I¯T .
Table 1. Example of Q¯Ik and Z¯Ik , k∈{1,3, ..,12,T,BF}
sector measurements in test patient PA2 shown in
Fig. 1. Succesive scans T1, pre chemotherapy, and
T2, post it. Both reference values are similar, on
both sides, and close to expected values 0.40 and
0.00, respectively. Similar results were observed in the
whole test set.
PA2 measurements
PA2 T1 T2
Anterior Posterior Anterior Posterior
Q¯I1 0.39 0.38 0.38 0.39
Z¯I1 -0.02 -0.03 -0.02 -0.02
Q¯IT 0.40 0.40 0.40 0.40
Z¯IT 0.00 0.00 0.00 0.00
Q¯I3 0.40 0.39 0.39 0.40
Z¯I3 0.00 0.00 0.00 0.00
Q¯I4 0.40 0.39 0.40 0.40
Z¯I4 0.00 0.00 0.00 0.00
Q¯I5 0.40 0.36 0.39 0.40
Z¯I5 0.00 0.00 0.00 0.00
Q¯I6 0.40 0.38 0.40 0.39
Z¯I6 0.00 0.00 0.00 0.00
Q¯I9 0.38 0.39 0.40 0.40
Z¯I9 0.00 0.00 0.00 0.00
Q¯I10 0.40 0.39 0.40 0.39
Z¯I10 0.00 0.00 0.00 0.00
Q¯I11 0.33 0.35 0.33 0.32
Z¯I11 0.00 0.00 0.00 0.00
Q¯I12 0.33 0.35 0.38 0.35
Z¯I12 0.00 0.00 0.00 0.00
Q¯IBF 0.39 0.40 0.36 0.39
Z¯IBF 0.00 0.00 0.00 0.00
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DISCUSSION
One of the big problems of all the existing mIBG
scores is the subjetivity of the interpretation of the
scans that makes very difficult the quantitation of the
response to treatment. Our series of patients, can be
considered as a pilot demonstration of the possibility
of truly quantify the extension of disease at diagnosis
and the response to treatment, avoiding inter-observer
variations.
In every analyzed 123I-mIBG of test set, the mean
of the standard Z-Score Z¯Ik for any SIOPEN body
sector Ik as well as Z¯IBF tends to be constant with value
close to 0.0. This fact enables us to take comparable
measurements with respect to the local counts average
at any SIOPEN sector I¯k. Z¯Ik and Z¯IBF equal to 0.00
is the common point of reference between scans of
the same patient, and even between different patients.
Regional comparisons to the predefined SIOPEN
sectors rather than to local lesion site reduces observer
dependent measurements.
In the same patient and the same scan, comparisons
between measurements Z¯Ik(ROI#) taken at ROIs of
same sector Ik are direct. For instance, objective
comparison between the specific uptake Z¯Ik(ROI#) due
to a possible tumour and non-specific uptake at liver
Z¯Ik(Liver) is possible.
Comparisons between ROIs located in different
SIOPEN sectors by using Z¯Ik(ROI#) and Z¯Ik′ (ROI#′)
could be deceptive in such cases where one of the
sectors has an abnormal counts increase, for instance,
due to a whole sector 123I-mIBG stain in skin.
Table 2. Comparison between qualitative informs (visible or not, more or less intense, etc.) and quantitative
meassurements of tumours in posterior views of scans T1 and T2 (quantitative difference in parentheses) of patient
PA4 (Fig. 2). Z¯IBF and Z¯IT are 0.0 at every scintigraphy. Both references enable to take quantitative comparisons
of uptake between scintigraphies. Q¯IBF and Q¯IT are close to 0.40 at each scan as expected. This is a reference
for comparisons to local sector average. Values of Q¯IT (ROI#) higher than 0.40 (Q¯IT ) means that the ROI# has an
abnormal value of counts, higher than the average of the trunk sector IT .
PA4 measurements
PA4 T1 T2 T3 T4
I¯T 0.29 0.40 0.16 0.29
Z¯IT 0.00 0.00 0.00 0.00
Q¯IT 0.39 0.40 0.38 0.39
Z¯IBF 0.00 0.00 0.00 0.00
Q¯IT (Liver) 0.92 0.95 0.78 1.09
Z¯IT (Liver) 0.84 0.86 0.67 1.05
Z¯IBF (Liver) 1.59 1.59 1.41 1.84
Qualitative Visible Not visible Not Visible Not Visible
Q¯IT (ROI1) 0.40 0.05 (−0.35) 0.03 (−0.02) 0.00 (−0.03)
Z¯IT (ROI1) 0.11 -0.56 (−0.67) -0.62 (−0.06) -0.71 (−0.09)
Z¯IBF (ROI1) 0.76 0.00(−0.76) -0.07 (−0.07) -0.16(−0.09)
Qualitative Visible Not visible More Intense Less Intense
Q¯IT (ROI2) 0.38 0.23 (−0.15) 0.90 (+0.67) 0.73 (−0.17)
Z¯IT (ROI2) 0.19 0.01(−0.18) 0.72 (+0.71) 0.66 (−0.06)
Z¯IBF (ROI2) 0.85 0.64 (−0.21) 1.23 (+0.59) 1.12 (−0.11)
Qualitative Visible Not visible Not Visible Not Visible
Q¯IT (ROI3) 0.05 0.00 (−0.05) 0.00(≈) 0.00(≈)
Z¯IT (ROI3) -0.61 -0.79 (−0.18) -0.87 (−0.08) -0.81(+0.06)
Z¯IBF (ROI3) -0.06 -0.26 (−0.20) -0.35(−0.09) -0.27(+0.08)
Qualitative Visible Not visible Not Visible Not Visible
Q¯IT (ROI4) 0.06 0.00 (−0.06) 0.02 (+0.02) 0.02 (≈)
Z¯IT (ROI4) -0.47 -0.68 (−0.21) -0.67(+0.01) -0.63(+0.04)
Z¯IBF (ROI4) 0.10 -0.14 (−0.24) -0.13(+0.01) -0.06 (+0.07)
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Fig. 4. Example of sector IT measurements in patients
PA2, PA4 and PA5. Although the radiodistribution is
very different in each patient, the value of Z¯IT is close
to 0.00 and Q¯IT is close to 0.40 in all of them. Same
results were observed in the whole test set.
In order to properly compare ROIs at different
sectors, the value of Z¯IBF (ROI#) of each ROI may
be used. The whole body counts average I¯BF is
used as the numeric reference for taking quantitative
measurements in the same way that it is already a
visual implicit reference for the human eye for the
qualitative assessment.
What is more, comparisons between non-specific
background uptake at any SIOPEN sector Z¯IBF (Ik)
with respect to the whole body frame Z¯IBF are also
possible. At limb sectors, for instance at Sector 9,
Z¯IBF (I9) measurement should be low in patients with
no metastatic sites at that sector. The increase of this
objective metric is an evidence of an abnormal uptake
at this sector with respect to the whole body, that is, a
possible metastatic site in bones.
This fact makes Z¯IBF (ROI#) a good candidate to
take standarized comparable measurements between
different patients and different scans. A database of
usual Z¯IBF (ROI#) values of tumour and metastases at
each SIOPEN sector could be used for comparisons in
cases of doubt.
Quantitative measurements Q¯Ik(ROI#) and the fact
that Q¯Ik is always close to 0.40 gives an intuitive visual
reference value of how intense is that ROI in reference
to the local counts average I¯k.
The use of Q¯IBF (ROI#) could be problematic
because it takes only positive values and it is related
to I¯BF . It is possible for a given ROI to be greater than
the average at its sector but lower than I¯BF and then
Q¯IBF (ROI#) would be 0.0. In such cases, the value of
Z¯IBF (ROI#) would be negative meaning that the ROI
has a counts average lower than the average at the
whole body frame IBF .
These results show that the use of Q¯Ik(ROI#) and
Q¯IBF (ROI#) could be useful for automatic detection of
abnormal uptake regions on image. If any region in
body has a value greater than Q¯IBF then it is bound to
be abnormal, because it is much too intense. Q¯Ik(ROI#)
could be used in the same manner.
Table 3. Results of measurements in anterior views of
scans of patients PA2 and PA6 in Fig. 3. Comparisons
between different patients are possible by using
Z¯IBF (ROI#) because it is referenced to body frame
counts average I¯BF and Z¯IBF has a value of 0.0 in every
scan of every patient.
PA2 and PA6 measurements
PA2 T1 T2
Z¯I1 0.00 0.00
Z¯IBF 0.00 0.00
Qualitative Not visible Visible
Q¯I1(ROI1) 0.05 0.14 (+0.09)
Z¯I1(ROI1) -0.53 -0.43 (+0.10)
Z¯IBF (ROI1) -0.56 -0.52 (+0.04)
Qualitative Not visible Visible
Q¯IT (ROI2) 0.00 0.53 (+0.53)
Z¯IT (ROI2) -0.84 0.15(+0.91)
Z¯IBF (ROI2) -0.30 1.01(+1.31)
Qualitative Not visible Visible
Q¯I12(ROI3) 0.64 0.90 (+0.26)
Z¯I12(ROI3) 0.39 0.75 (+0.36)
Z¯IBF (ROI3) -0.80 -0.57 (+0.23)
PA6 T1 T2
Z¯I1 0.00 0.00
Z¯IBF 0.00 0.00
Qualitative Not visible Visible
Q¯I1(ROI1) 0.07 0.50 (+0.43)
Z¯I1(ROI1) -0.42 0.07 (+0.49)
Z¯IBF (ROI1) -0.44 -0.16(+0.38)
Qualitative Not visible Visible
Q¯IT (ROI2) 0.08 0.59(+0.51)
Z¯IT (ROI2) -0.63 0.22(+0.85)
Z¯IBF (ROI2) 0.13 0.98(+0.85)
Qualitative Not visible Visible
Q¯I12(ROI3) 0.51 0.94(+0.43)
Z¯I12(ROI3) 0.19 0.79(+0.80)
Z¯IBF (ROI3) -0.95 -0.25(+0.70)
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CONCLUSIONS
In this paper we propose the application of
a method to take objective observer independent
measurement of the specific 123I-mIBG uptake at any
region of interest in reference to the SIOPEN sector
where it is located.
When response to treatment is light, low definition
in scan may make impossible to the human eye
to appreciate changes in the intensity. Z¯IBF (ROI#),
Z¯Ik(ROI#) and Q¯Ik(ROI#) measurements may assist in
the application of SIOPEN validated semi-quantitative
scoring method as an additional tool for measuring
and comparing 123I-mIBG uptake in doubt cases in
which differences in assessment between observers
could appear.
Z¯IBF (ROI#) is a measuring tool for absolute
comparison between any regions and between patients
and scans. It has an intuitive measurement of how
much a region of interest stands out among the rest of
the body. It enables to take objective measurements of
uptake in a region in reference to the whole body frame
counts average to precise the increase or decrease of
uptake in that region in comparison with previous
scans of the same or other patient.
Q¯Ik(ROI#) and Z¯Ik(ROI#) enable the objective
comparison of the specific uptake measurements
at different ROIs inside the same SIOPEN sector.
They are referenced to the local counts average at
SIOPEN sector k. Q¯Ik(ROI#) has shown an intuitive
interpretation. It is close to 0.00 when the uptake at
region is hardly visible. As uptake increases, the peak
is more visible and Q¯Ik(ROI#) increases accordingly
taking values lower than 0.40 when is not intense
and higher than 0.40 when it is a very intense peak.
At limbs, the significance of Q¯Ik(ROI#) is slightly
different, that is, values close to 0.40 of any ROI are
due to peaks more intense (and abnormal) at trunk than
in limbs, where uptake peaks reach higher Q¯Ik(ROI#)
values.
Q¯Ik(ROI#) greater than 0.40 is a good candidate
to automatically detect abnormal uptake in head and
trunk sectors. That is, any region in sector with
Q¯Ik(ROI#) greater than 0.40 has a high abnormal
uptake value and is very likely to be an abnormal
uptake peak. But, in limb sectors, due to the low counts
average, there are always regions with values greater
than 0.40 although they are not visible (they are not
abnormal peaks).
In such sectors, for automatic detection, the values
of Z¯IBF (ROI#) should be used because it is referenced
to whole body counts average I¯BF . At any sector, a
region with a value Q¯IBF (ROI#) greater than 0.40 could
be automatically identified as abnormal.
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